Evidence suggests osimertinib has better CNS penetration than afatinib and may provide better clinical outcomes in patients with bone metastasis, therefore we recommend it over other EGFR TKIs in patients with CNS or bone involvement. The gene discussed is EGFR; the disease is bone metastasis.